Phase 3 trial in 440 patients with stage III-IV oropharyngeal cancer: proton therapy was non-inferior to IMRT for progression-free survival (3-year 82.5% vs 83.0%) and had higher 5-year overall survival (90.9% vs 81.0%) and less dysphagia and xerostomia.
RCTn = 440
Frank et al. Proton versus photon radiotherapy for patients with oropharyngeal cancer in the USA: a multicentre, randomised, open-label, non-inferiority phase 3 trial